Australian Streptokinase Trial "ASK"


Phase 3 Results

Trial Description

To determine whether the administration of 1.5 million units of streptokinase intravenously within 4 hours of the onset of acute ischemic stroke would reduce morbidity and mortality at 3 months and whether outcomes may be better for those receiving therapy within 3 hours of stroke onset compared with those receiving it after 3 hours.


  • Streptokinase (Streptase┬«)Drug
    Intervention Desc: Thrombolytic agent

Trial Design

Randomized, double-blind, placebo-controlled trial involving 340 patients at 40 centers throughout Australia.

Patient Involvement

Administration of 1.5 million units of streptokinase or placebo intravenously in 100 mL of normal saline over 1 hour with 3 month follow-up.


Type Measure Time Frame Safety Issue
Primary Combined death and disability score (Barthel index <60) 3 months after the stroke.